***TASK*** the task is to summarize an input biomedical literature in six sentences 
    ***INPUT*** the input is a biomedical literature 
    ***OUTPUT*** the output is the summary of an input biomedical literature in six sentences 
    ***DOCUMENTATION*** 
    ***EXAMPLES*** 
    Input: Background — Monitoring implantable cardiac device function and patient condition is important . The Lumos-T Safely Reduces Routine Office Device Follow-Up ( TRUST ) trial tested the hypothesis that remote home monitoring with automatic daily surveillance ( HM ) is safe and effective for implantable cardioverter-defibrillator follow-up for 1 year and enables rapid physician evaluation of significant events . Methods and Results — In total , 1339 patients were r and omized 2:1 to HM or conventional follow-up . Follow-up checks occurred at 3 , 6 , 9 , 12 , and 15 months after implantation . HM was used before office visits at 3 and 15 months in the HM group . At 6 , 9 , and 12 months , HM only was used but was followed by office visits if necessary . Conventional patients were evaluated with office visits only . Scheduled office visits and unscheduled evaluations , incidence of morbidity , and time elapsed from first event occurrence in each patient to physician evaluation were tracked for each group .  HM and conventional patients were similar ( age , 63.3±12.8 versus 64.0±12.1 years ; gender , 72.0 % versus 73.1 % male ; New York Heart Association class II , 55.9 % versus 60.4 % ; pathology : left ventricular ejection fraction , 29.0±10.7 % versus 28.5±9.8 % ; coronary artery disease , 64.8 % versus 71.7 % ; primary prevention indication , 72.2 % versus 73.8 % ; and dual-chamber implants , 57.8 % versus 56.6 % ) . HM  reduced total in-hospital device evaluations by 45 % without affecting morbidity . In the HM group , 85.8 % of all 6- , 9- , and 12-month follow-ups were performed remotely only , indicating that HM provided sufficient assessment in the majority . Median time to evaluation was < 2 days in the HM group compared with 36 days in the conventional group ( P<0.001 ) for all arrhythmic events . Conclusions — HM is safe and allows more rapid detection of actionable events compared with conventional monitoring in patients with implantable electronic cardiac devices . Clinical Trials Registration — URL : http:/www . clinical trials.gov . Unique identifier : NCT00336284 Background Synthesis of multiple r and omized controlled trials ( RCTs ) in a systematic review can summarize the effects of individual outcomes and provide numerical answers about the effectiveness of interventions . Filtering of search es is time consuming , and no single method fulfills the principal requirements of speed with accuracy . Automation of systematic review s is driven by a necessity to expedite the availability of current best evidence for policy and clinical decision-making . We developed Rayyan ( http://rayyan.qcri.org ) , a free web and mobile app , that helps expedite the initial screening of abstract s and titles using a process of semi-automation while incorporating a high level of usability . For the beta testing phase , we used two published Cochrane review s in which included studies had been selected manually . Their search es , with 1030 records and 273 records , were uploaded to Rayyan . Different features of Rayyan were tested using these two review s. We also conducted a survey of Rayyan ’s users and collected feedback through a built-in feature . Results Pilot testing of Rayyan focused on usability , accuracy against manual methods , and the added value of the prediction feature . The “ taster ” review ( 273 records ) allowed a quick overview of Rayyan for early comments on usability . The second review ( 1030 records ) required several iterations to identify the previously identified 11 trials . The “ suggestions ” and “ hints , ” based on the “ prediction model , ” appeared as testing progressed beyond five included studies . Post rollout user experiences and a reflexive response by the developers enabled real-time modifications and improvements . The survey respondents reported 40 % average time savings when using Rayyan compared to others tools , with 34 % of the respondents reporting more than 50 % time savings . In addition , around 75 % of the respondents mentioned that screening and labeling studies as well as collaborating on review s to be the two most important features of Rayyan . As of November 2016 , Rayyan users exceed 2000 from over 60 countries conducting hundreds of review s totaling more than 1.6 M citations . Feedback from users , obtained mostly through the app web site and a recent survey , has highlighted the ease in exploration of search es , the time saved , and simplicity in sharing and comparing include-exclude decisions . The strongest features of the app , identified and reported in user feedback , were its ability to help in screening and collaboration as well as the time savings it affords to users . Conclusions Rayyan is responsive and intuitive in use with significant potential to lighten the load of review ers Abstract Aims Remote management of heart failure using implantable electronic devices ( REM-HF ) aim ed to assess the clinical and cost-effectiveness of remote monitoring ( RM ) of heart failure in patients with cardiac implanted electronic devices ( CIEDs ) . Methods and results Between 29 September 2011 and 31 March 2014 , we r and omly assigned 1650 patients with heart failure and a CIED to active RM or usual care ( UC ) . The active RM pathway included formalized remote follow-up protocol s , and UC was st and ard practice in nine recruiting centres in Engl and . The primary endpoint in the time to event analysis was the 1st event of death from any cause or unplanned hospitalization for cardiovascular reasons . Secondary endpoints included death from any cause , death from cardiovascular reasons , death from cardiovascular reasons and unplanned cardiovascular hospitalization , unplanned cardiovascular hospitalization , and unplanned hospitalization . REM-HF is registered with IS RCT N ( 96536028 ) . The mean age of the population was 70 years ( range 23–98 ) ; 86 % were male . Patients were followed for a median of 2.8 years ( range 0–4.3 years ) completing on 31 January 2016 . Patient adherence was high with a drop out of 4.3 % over the course of the study . The incidence of the primary endpoint did not differ significantly between active RM and UC groups , which occurred in 42.4 and 40.8 % of patients , respectively [ hazard ratio 1.01 ; 95 % confidence interval ( CI ) 0.87–1.18 ; P = 0.87 ] . There were no significant differences between the two groups with respect to any of the secondary endpoints or the time to the primary endpoint components . Conclusion Among patients with heart failure and a CIED , RM using weekly downloads and a formalized follow up approach does not improve outcomes OBJECTIVES The purpose of this study was to determine whether a heart failure ( HF ) management strategy using continuous intracardiac pressure monitoring could decrease HF morbidity . BACKGROUND Patients with HF may experience frequent decompensations that require hospitalization despite intensive treatment and follow-up . METHODS The COMPASS-HF ( Chronicle Offers Management to Patients with Advanced Signs and Symptoms of Heart Failure ) study was a prospect i ve , multicenter , r and omized , single-blind , parallel-controlled trial of 274 New York Heart Association functional class III or IV HF patients who received an implantable continuous hemodynamic monitor . Patients were r and omized to a Chronicle ( Medtronic Inc. , Minneapolis , Minnesota ) ( n = 134 ) or control ( n = 140 ) group . All patients received optimal medical therapy , but the hemodynamic information from the monitor was used to guide patient management only in the Chronicle group . Primary end points included freedom from system-related complications , freedom from pressure-sensor failure , and reduction in the rate of HF-related events ( hospitalizations and emergency or urgent care visits requiring intravenous therapy ) . RESULTS The 2 safety end points were met with no pressure-sensor failures and system-related complications in only 8 % of the 277 patients who underwent implantation ( all but 4 complications were successfully resolved ) . The primary efficacy end point was not met because the Chronicle group had a nonsignificant 21 % lower rate of all HF-related events compared with the control group ( p = 0.33 ) . A retrospective analysis of the time to first HF hospitalization showed a 36 % reduction ( p = 0.03 ) in the relative risk of a HF-related hospitalization in the Chronicle group . CONCLUSIONS The implantable continuous hemodynamic monitor-guided care did not significantly reduce total HF-related events compared with optimal medical management . Additional trials will be necessary to establish the clinical benefit of implantable continuous hemodynamic monitor-guided care in patients with advanced HF INTRODUCTION Remote monitoring is increasingly becoming the new st and ard of care for implantable cardioverter defibrillator ( ICD ) follow-up . We sought to determine whether remote monitoring of ICDs improves patient outcomes compared with quarterly device interrogations in clinic . METHODS AND RESULTS In this single-center pilot clinical trial , adult patients with an ICD were r and omly assigned to remote monitoring versus quarterly device interrogations in clinic . The primary endpoint was a composite of cardiovascular hospitalization , emergency room visit for a cardiac cause , and unscheduled visit to the electrophysiology clinic for a device-related issue at 1 year . We also examined health-related quality of life , costs , and patient satisfaction with their ICD care . Of 151 patients enrolled in this trial , 76 were r and omized to remote monitoring and 75 to quarterly device  interrogations in clinic . There was no significant difference in the primary endpoint ( 32 % in the remote monitoring arm vs 34 % in the control arm ; P = 0.8 ) , mortality , or cost between the 2 arms . Quality of life and patient satisfaction were significantly better in the control arm than in the remote monitoring arm at 6 months ( 83 [ 25th , 75th percentiles 70 , 90 ] vs 75 [ 50 , 85 ] ; P = 0.002 and 88 [ 75 , 100 ] vs 75 [ 75 , 88 ] ; P = 0.03 , respectively ) , but not at 12 months . CONCLUSION We showed no significant reduction in cardiac-related re source utilization with remote monitoring of ICDs . However , given the small number of patients in our study , the real clinical and health economics impact of remote monitoring needs to be verified by a large , multicenter , r and omized clinical trial AIMS To assess the usefulness of intrathoracic impedance monitoring ( IIM ) alerts in guiding empirical treatment of chronic heart failure ( CHF ) patients to prevent heart failure ( HF ) hospitalizations and unplanned HF care . METHODS AND RESULTS Chronic heart failure patients with OptiVol or CorVue capable implantable cardioverter-defibrillators were r and omized to either the active group ( IIM alarm turned on and diuretic dose increased by 50 % for 1 week in the event of alarm sounding ) or the control group ( IIM alarm turned off ) . The primary endpoint was the number of HF hospitalizations per patient at 1 year . The NYHA class , 6MWT , B-type natriuretic peptide ( BNP ) , and MLWHF question naire score were collected at baseline and follow-up . Eighty patients were included and 71 reached 1-year follow-up . There were 1.7 ± 1.5 alerts in the active group and 1.1 ± 1.0 in the control group , P = 0.07 . In the active group , 61 % of alerts led to a diuretic dose increase . There was a total of 11 HF hospitalizations in the active group vs. 6 in the control group without significant differences in the number of episodes per patient ( 0.3 ± 0.9 vs. 0.2 ± 0.4 , P = 0.95 ) . There were no unplanned HF visits in the active group vs. 0.1 ± 0.3 per patient in the control group , P = 0.08 . The total MLWHF scores were significantly increased at the final follow-up in the control group , whereas a trend towards reduction was observed in the active group . CONCLUSION In this study , an empirical HF treatment guided by IIM alerts did not reduce emergency treatment of HF . However , it seems to have a positive impact on quality of life . CLINICAL TRIAL REGISTRATION URL : http://www . clinical trials.gov . Unique identifier : NCT01320007 AIMS Only limited comparative data exist on the benefits of fluid monitoring ( FM ) combined with remote monitoring ( RM ) regarding morbidity and mortality of heart failure ( HF ) patients . This prospect i ve single-centre r and omized pilot study aim ed to estimate the influence of RM in combination with FM on HF hospitalizations as well as ventricular tachyarrhythmias and mortality . METHODS AND RESULTS Patients with st and ard indication for implantable cardioverter defibrillator ( ICD ) or cardiac resynchronization therapy and defibrillator were implanted with devices capable of RM and FM , and were followed for 15 months . Subjects were r and omly allocated to RM including OptiVol and predefined management of alerts ( remote group ) , or st and ard in-office visits every 3 months ( control group ) . A total of 176 patients ( 77 % male ; 66 ± 12 years ; left ventricular ejection fraction ( LVEF ) 32 ± 11 % ; ischemic cardiomyopathy 50 % ; CRT device 50 % ; primary prevention 85 % ) were analysed . Cox proportional hazard analysis on the time to first HF-related hospitalization showed a hazard ratio of 1.23 [ 0.62 - 2.44 
    Output:
    
RM showed benefit in reducing HF-related hospitalization when compared to st and ard of care only when using pulmonary pressure monitoring